Regorafenib Intermediate Supply Chain Risk & Patent Compliance
Assessing WO2016005874A1 Patent Claims on 4-(4-Amino-3-fluorophenoxy)-N-methylpicolinamide Synthesis Routes
The intellectual property landscape surrounding Regorafenib intermediates is complex, particularly concerning patent WO2016005874A1. This patent delineates specific synthesis routes for 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide, a critical precursor in the manufacturing of the multi-kinase inhibitor Regorafenib. For procurement managers and R&D directors, understanding the claims within this patent is essential to avoid infringement risks during scale-up. The patent emphasizes specific catalytic conditions and purification steps that differentiate compliant manufacturing from generic synthesis.
At NINGBO INNO PHARMCHEM CO.,LTD., we engineer our production processes to navigate these claims while maintaining high yield efficiency. A critical engineering consideration often overlooked in standard technical data sheets is the thermal degradation threshold of the picolinamide derivative during the amidation step. While standard COAs report assay purity, they rarely specify the kinetic stability of the intermediate when exposed to transient heat spikes above 60°C during reactor discharge. Our field data indicates that uncontrolled exothermic events during this phase can lead to trace dimerization, which complicates downstream purification. Ensuring your supplier monitors this non-standard parameter is vital for long-term process stability.
Establishing >99.5% HPLC Purity Grades for Regorafenib Intermediate IP Compliance
Achieving IP compliance requires more than just meeting a minimum assay percentage. For Regorafenib intermediate supply chain risk mitigation, the purity profile must align with the stringent requirements of modern oncology drug manufacturing. The market demand for Regorafenib tablets, driven by indications in colorectal cancer and hepatocellular carcinoma, necessitates intermediates with consistent impurity profiles. We target >99.5% HPLC purity to ensure that downstream synthesis does not accumulate unacceptable levels of related substances.
The following table outlines the technical differentiation between standard commercial grades and those engineered for IP compliance and high-grade API synthesis:
| Parameter | Standard Commercial Grade | IP Compliance Grade | Test Method |
|---|---|---|---|
| Assay (HPLC) | >98.0% | >99.5% | Area Normalization |
| Single Largest Impurity | <0.5% | <0.10% | HPLC |
| Total Impurities | <1.0% | <0.5% | HPLC |
| Residual Solvents | Meets General Spec | ICH Q3C Compliant | GC Headspace |
| Heavy Metals | <20 ppm | <10 ppm | ICP-MS |
Procurement teams should verify that the provided Certificate of Analysis reflects these tighter tolerances, particularly for the single largest impurity, as this directly impacts the safety profile of the final API.
Auditing COA Parameters for Residual Solvents and Chiral Impurities Under Patent Restrictions
When auditing a supplier, the Certificate of Analysis (COA) must be scrutinized beyond the main assay. Residual solvents used during the crystallization of the fluorophenoxy compound can persist if drying protocols are insufficient. Under patent restrictions, specific solvents may be mandated or prohibited to avoid process infringement. Furthermore, while 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide is not chiral itself, the presence of chiral impurities from upstream starting materials can carry through.
For organizations currently evaluating a Synthonix Sy3H5815F400 alternative supplier, it is crucial to compare the impurity fingerprint of the new source against existing validated batches. Discrepancies in the residual solvent profile, such as elevated levels of polar aprotic solvents, can trigger additional regulatory testing during API filing. We recommend requesting a full impurity profile report alongside the standard COA to ensure alignment with your quality agreements.
Aligning Storage Conditions and Shelf-Life Specs with WO2016005874A1 Compliance Standards
Storage conditions are not merely logistical details; they are compliance parameters. The stability of the picolinamide derivative is sensitive to humidity and temperature fluctuations. Standard specifications often suggest storage at ambient temperatures, but field experience suggests that prolonged exposure to relative humidity above 60% can lead to hygroscopic uptake, affecting flowability during automated dispensing.
Additionally, thermal stability data indicates that while the compound is stable at room temperature, the thermal degradation threshold becomes relevant during summer shipping or storage in non-climate-controlled warehouses. We advise maintaining storage temperatures below 25°C to prevent minor degradation pathways that might not be immediately visible but could affect reaction kinetics in the subsequent step. For detailed information on bulk CAS 757251-39-1 pricing and technical specs, reviewing the economic implications of climate-controlled logistics versus standard warehousing is recommended for total cost of ownership analysis.
Engineering Bulk Packaging Solutions to Mitigate Regorafenib Intermediate Supply Chain Risk
Supply chain resilience relies heavily on physical packaging integrity. For bulk quantities, we utilize 25kg fiber drums with polyethylene liners or 500kg IBC totes depending on volume requirements. The focus here is on preventing moisture ingress and physical contamination during transit. Unlike regulatory certifications, physical packaging engineering ensures that the chemical integrity remains intact from the manufacturing site to your production floor.
Our 4-(4-Amino-3-fluorophenoxy)-N-methylpicolinamide product page provides further details on available packaging configurations. By standardizing on high-density polyethylene liners and ensuring drum seals are torque-tested, we mitigate the risk of contamination that could lead to batch rejection. This physical security is a cornerstone of managing Regorafenib intermediate supply chain risk, ensuring that the material arriving at your facility matches the quality of the material that left ours.
Frequently Asked Questions
What is the standard lead time for bulk orders of this intermediate?
Standard lead times vary based on current production schedules and inventory levels, typically ranging from 2 to 4 weeks for established grades. Please refer to the batch-specific COA for current stock availability.
Can you provide custom synthesis for modified derivatives?
Yes, we offer custom synthesis services for modified picolinamide derivatives subject to feasibility studies and non-disclosure agreements.
What documentation is provided with each shipment?
Each shipment includes a Certificate of Analysis, a Statement of Quality, and detailed packaging documentation to ensure traceability and compliance with commercial terms.
How are residual solvents tested in your facility?
Residual solvents are tested using Gas Chromatography with Headspace sampling, adhering to ICH Q3C guidelines where applicable.
Sourcing and Technical Support
Securing a reliable source for critical oncology intermediates requires a partner with deep technical expertise and robust engineering controls. NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing high-purity intermediates that meet the rigorous demands of pharmaceutical manufacturing. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.